U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

der the Paperwork Reduction Act of 1995, no persons are required

(use as many sheets as necessary) Sheet 1 of 2

to respond to a collection of information unit	iss it displays a valid OMB control numbe
Confirmation Number	5753
Application Number	09/698,454
Filing Date	10-27-2000
First Named Inventor	Miri Seiberg
Group Art Unit	1617
Examiner Name	Yong Soo Chong
Attorney Docket Number	JBP0518US

		U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
Exam Initials	Cite No.1	Number (if known)				
		2,876,164		Wershaw	03-03-1959	
		2007/0160564	A1	Liu et al.	07-12-2007	(J&J2001USDIV1)

				FORI	EIGN PATENT DOCUMENTS			
Exam Cite Initials No.1		Foreign Patent Document Office ⁹ Number ⁴ KindCode ⁵			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T _e
		EP	0 532 465	Α	Pentapharm AG	03-17-1993		Yes
		JP	10-046196	Α	Shiga	02-17-1998		Yes
		JP	10-175815	Α	Shiga	06-30-1998	Abstract	
		JP	2001-271096	Α	TKC Takahashi Comp Kaikei	10-02-2001	Abstract	
		wo	2001/029163	Α	Henkel	04-26-2001		Yes
		wo	2004/022024	Α	J&J Consumer France	03-18-2004		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²		
		PENTAPHARM, Product "ELHIBIN®" product catalog.			
		PENTAPHARM, Product "ELHIBIN®" product catalog (1998)	Yes		
		WENNINGER, ET AL, International Cosmetic Ingredient Dictionary and Handbook, 7 th edition, vol. 2 (1997), "SOYBEAN (GLYCINE SOJA) PROTEIN", page 1332-1333.			

Exan	iner	Date	
Signa	ture	Considered	
*EYAN	INFR: Initial if reference considered, whether or not citation is in conformance with	MPEP 609. Draw fine through citati	on if not in conformance

*EXAMINES. Initial if reference considered, whether or not citation is in conformance with IMEP 600. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicants unique citation designation unimber (optional), see Kinds Codes of U.S. Patert Documents at <u>www.sapro.cy</u>. Enter Office that issued the document, by the two-tester code (WIPO Standard ST.3), 4 For Japanese patent documents, the indication of the year of the region or must procede the estimal number of the part document, such of document of which is the patent document, such of document of the part of the Emperor must procede the estimal number of the patent document, skill not document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Frankation is attached.

This collection of information is required by 37 CRF 1.97 and 1.98. The information required to obtain or retain a benefit by the public which by the USPTO on processe) an application. Confidentiality is governed by 58 U.S. C. 122 and 37 CRF 1.14. This collection is explicated to itse? to simple, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary operating upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Cultification (FIGE. U.S. Petert and Tademark Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria. VA 2213-1.450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria. VA 2213-1.450.